lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% A new clinical trial from

*Based on STEP 1 pharmaceutical trial

It was discontinued in 2008 due to manufacturing issues (not safety concerns) and is still available through compounding pharmacies

It is the first of these medications to interact with two hormones in the body, which is why researchers believe it manages blood sugar levels better than previous medicines and helps people lose more weight

Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, Wada H, Hasegawa K, Shimatsu A, Satoh-Asahara N

The ingredients in Activate, particularly the combination of hibiscus and lemon verbena polyphenols, have been shown in clinical studies to modestly increase GLP-1 levels (12-22% above baseline)